Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 2
2004 4
2005 5
2006 1
2007 1
2008 5
2009 6
2010 1
2012 1
2014 4
2015 5
2016 6
2017 1
2018 3
2019 2
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

57 results
Results by year
Filters applied: . Clear all
Page 1
Break-out session highlights.
Myhr KM, Mäurer M, Ginés MM, Esposito F, Linker R. Myhr KM, et al. Among authors: maurer m. Neurodegener Dis Manag. 2017 Nov;7(6s):45-49. doi: 10.2217/nmt-2017-0042. Neurodegener Dis Manag. 2017. PMID: 29143586
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators. Trojano M, et al. Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2. Mult Scler Relat Disord. 2018. PMID: 29860197 Free article.
Web-based interventions in multiple sclerosis: the potential of tele-rehabilitation.
Tallner A, Pfeifer K, Mäurer M. Tallner A, et al. Among authors: maurer m. Ther Adv Neurol Disord. 2016 Jul;9(4):327-35. doi: 10.1177/1756285616640684. Epub 2016 Apr 6. Ther Adv Neurol Disord. 2016. PMID: 27366240 Free PMC article. Review.
Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases.
Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Abraham A, Althaus K, Becks G, Berrouschot J, Berthel J, Bode FJ, Burghaus L, Cangür H, Daffertshofer M, Edelbusch S, Eggers J, Gerlach R, Gröschel K, Große-Dresselhaus F, Günther A, Haase CG, Haensch CA, Harloff A, Heckmann JG, Held V, Hieber M, Kauert A, Kern R, Kerz T, Köhrmann M, Kraft P, Kühnlein P, Latta J, Leinisch E, Lenz A, Leithner C, Neumann-Haefelin T, Mäurer M, Müllges W, Nolte CH, Obermann M, Partowi S, Patzschke P, Poli S, Pulkowski U, Purrucker J, Rehfeldt T, Ringleb PA, Röther J, Rossi R, El-Sabassy H, Sauer O, Schackert G, Schäfer N, Schellinger PD, Schneider A, Schuppner R, Schwab S, Schwarte O, Seitz RJ, Senger S, Shah YP, Sindern E, Sparenberg P, Steiner T, Szabo K, Urbanek C, Sarnowksi BV, Weissenborn K, Wienecke P, Witt K, Wruck R, Wunderlich S. Kermer P, et al. Among authors: maurer m. Int J Stroke. 2020 Aug;15(6):609-618. doi: 10.1177/1747493019895654. Epub 2020 Jan 19. Int J Stroke. 2020. PMID: 31955706
Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence.
Bayas A, Mäurer M. Bayas A, et al. Among authors: maurer m. Patient Prefer Adherence. 2015 Feb 9;9:265-74. doi: 10.2147/PPA.S61651. eCollection 2015. Patient Prefer Adherence. 2015. PMID: 25709412 Free PMC article. Review.
Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey.
Bass AD, Van Wijmeersch B, Mayer L, Mäurer M, Boster A, Mandel M, Mitchell C, Sharrock K, Singer B. Bass AD, et al. Among authors: maurer m. Int J MS Care. 2020 Jul-Aug;22(4):158-164. doi: 10.7224/1537-2073.2018-087. Epub 2019 Aug 28. Int J MS Care. 2020. PMID: 32863783 Free PMC article.
Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis.
Wehrum T, Beume LA, Stich O, Mader I, Mäurer M, Czaplinski A, Weiller C, Rauer S. Wehrum T, et al. Among authors: maurer m. Neurology. 2018 Feb 13;90(7):e601-e605. doi: 10.1212/WNL.0000000000004950. Epub 2018 Jan 19. Neurology. 2018. PMID: 29352101
Rehabilitation in multiple sclerosis: the role of tele-rehabilitation/gaming.
Mäurer M. Mäurer M. Neurodegener Dis Manag. 2016 Dec;6(6s):17-18. doi: 10.2217/nmt-2016-0049. Neurodegener Dis Manag. 2016. PMID: 27874500 No abstract available.
Animal models of immune-mediated neuropathies.
Mäurer M, Gold R. Mäurer M, et al. Curr Opin Neurol. 2002 Oct;15(5):617-22. doi: 10.1097/00019052-200210000-00013. Curr Opin Neurol. 2002. PMID: 12352006 Review.
Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
Huhn K, Bayas A, Doerck S, Frank B, Gerbershagen K, Hellwig K, Kallmann B, Kleinschnitz C, Kleiter I, Lee DH, Limmroth V, Mäurer M, Meuth S, Rieckmann P, Ruck T, Gold R, Linker RA. Huhn K, et al. Among authors: maurer m. J Neurol. 2018 Jul;265(7):1521-1527. doi: 10.1007/s00415-018-8871-2. Epub 2018 Apr 25. J Neurol. 2018. PMID: 29696498
57 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback